HPC-A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control
It has been shown that it is possible to predict the CD 34+ hematopoietic progenitor cell dose from collection procedures on TerumoBCT COBE Spectra® cell separator platform using simple variables available at the start of the procedure. In this article, we demonstrate that this can be done simply an...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical apheresis 2015-12, Vol.30 (6), p.321-328 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 328 |
|---|---|
| container_issue | 6 |
| container_start_page | 321 |
| container_title | Journal of clinical apheresis |
| container_volume | 30 |
| creator | Cousins, Antony F. Sinclair, Joy E. Alcorn, Michael J H.A. Green, Rachel Douglas, Kenny W. |
| description | It has been shown that it is possible to predict the CD 34+ hematopoietic progenitor cell dose from collection procedures on TerumoBCT COBE Spectra® cell separator platform using simple variables available at the start of the procedure. In this article, we demonstrate that this can be done simply and reliably using TerumoBCT Spectra Optia® (“Optia”) cell separator platform with a very close correlation between predicted and actual results (correlation coefficient 0.956). This knowledge can be used to optimize apheresis sessions and to minimize harmful effects and costs. In addition, we have shown differences in collection efficiency between healthy donors and cancer patients undergoing autologous donation. Finally, we have shown a small but significant improvement in collection efficiency for the Optia platform compared with the COBE Spectra platform. J. Clin. Apheresis 30:321–328, 2015. © 2015 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/jca.21380 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1757517499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3923426471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4610-dfaeb286cf01f46bd83eb427f76054c7e1eb57de8e5f805a7d4f6238087ebbb63</originalsourceid><addsrcrecordid>eNp1kdGK1DAUhoMo7jh64QtIwCvB7iZt07TeDXWdURZdRNG7kKQnbsa06SYddseH8son8MnM2N3FGyEQ-P__fAfOj9BTSo4pIfnJVsvjnBY1uYcWlDR1Rimh99GC8KLI8pI1R-hRjFtCSNMU7CE6yllFG97QBfq1OW-zFe58BDwG6KyerB9wetMFYD9OVv7-iTU4hyOMMsjJB6xkhO6QkVjBoC96Gb7j9jTH2jsHMwGMsdomd_8Knwff-8kO37B2drBaun_sl7hPWm9_HPzJXyd5SqIcOiyd81cH-XInXVITf5iCd4_RAyNdhCc3_xJ9fnP6qd1kZx_Wb9vVWabLipKsMxJUXlfaEGrKSnV1AarMueEVYaXmQEEx3kENzNSESd6VpsrTGWsOSqmqWKLnM3cM_nIHcRJbvwtDWikoZ5xRXqaDLtGLOaWDjzGAEWOw6SR7QYk49CNSP-JvPyn77Ia4Uz10d8nbQlLgZA5cWQf7_5PEu3Z1i8zmCRsnuL6bSJWIiheciS_v14K9bslm_ZWJj8UfQg-svg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1757517499</pqid></control><display><type>article</type><title>HPC-A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Cousins, Antony F. ; Sinclair, Joy E. ; Alcorn, Michael J ; H.A. Green, Rachel ; Douglas, Kenny W.</creator><creatorcontrib>Cousins, Antony F. ; Sinclair, Joy E. ; Alcorn, Michael J ; H.A. Green, Rachel ; Douglas, Kenny W.</creatorcontrib><description>It has been shown that it is possible to predict the CD 34+ hematopoietic progenitor cell dose from collection procedures on TerumoBCT COBE Spectra® cell separator platform using simple variables available at the start of the procedure. In this article, we demonstrate that this can be done simply and reliably using TerumoBCT Spectra Optia® (“Optia”) cell separator platform with a very close correlation between predicted and actual results (correlation coefficient 0.956). This knowledge can be used to optimize apheresis sessions and to minimize harmful effects and costs. In addition, we have shown differences in collection efficiency between healthy donors and cancer patients undergoing autologous donation. Finally, we have shown a small but significant improvement in collection efficiency for the Optia platform compared with the COBE Spectra platform. J. Clin. Apheresis 30:321–328, 2015. © 2015 Wiley Periodicals, Inc.</description><identifier>ISSN: 0733-2459</identifier><identifier>EISSN: 1098-1101</identifier><identifier>DOI: 10.1002/jca.21380</identifier><identifier>PMID: 25619791</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Antigens, CD34 - metabolism ; Benchmarking ; Blood Component Removal - instrumentation ; Blood Component Removal - standards ; Blood Component Removal - statistics & numerical data ; Cell Count ; Cell Separation - instrumentation ; Cell Separation - standards ; Cell Separation - statistics & numerical data ; Child ; Child, Preschool ; collection efficiency ; Female ; Hematopoietic Stem Cell Mobilization ; hematopoietic stem cells ; Hematopoietic Stem Cells - cytology ; Hematopoietic Stem Cells - immunology ; Humans ; Infant ; Male ; Middle Aged ; optia ; peripheral CD34 count ; Quality Control ; Retrospective Studies</subject><ispartof>Journal of clinical apheresis, 2015-12, Vol.30 (6), p.321-328</ispartof><rights>2015 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4610-dfaeb286cf01f46bd83eb427f76054c7e1eb57de8e5f805a7d4f6238087ebbb63</citedby><cites>FETCH-LOGICAL-c4610-dfaeb286cf01f46bd83eb427f76054c7e1eb57de8e5f805a7d4f6238087ebbb63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjca.21380$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjca.21380$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25619791$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cousins, Antony F.</creatorcontrib><creatorcontrib>Sinclair, Joy E.</creatorcontrib><creatorcontrib>Alcorn, Michael J</creatorcontrib><creatorcontrib>H.A. Green, Rachel</creatorcontrib><creatorcontrib>Douglas, Kenny W.</creatorcontrib><title>HPC-A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control</title><title>Journal of clinical apheresis</title><addtitle>J. Clin. Apheresis</addtitle><description>It has been shown that it is possible to predict the CD 34+ hematopoietic progenitor cell dose from collection procedures on TerumoBCT COBE Spectra® cell separator platform using simple variables available at the start of the procedure. In this article, we demonstrate that this can be done simply and reliably using TerumoBCT Spectra Optia® (“Optia”) cell separator platform with a very close correlation between predicted and actual results (correlation coefficient 0.956). This knowledge can be used to optimize apheresis sessions and to minimize harmful effects and costs. In addition, we have shown differences in collection efficiency between healthy donors and cancer patients undergoing autologous donation. Finally, we have shown a small but significant improvement in collection efficiency for the Optia platform compared with the COBE Spectra platform. J. Clin. Apheresis 30:321–328, 2015. © 2015 Wiley Periodicals, Inc.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antigens, CD34 - metabolism</subject><subject>Benchmarking</subject><subject>Blood Component Removal - instrumentation</subject><subject>Blood Component Removal - standards</subject><subject>Blood Component Removal - statistics & numerical data</subject><subject>Cell Count</subject><subject>Cell Separation - instrumentation</subject><subject>Cell Separation - standards</subject><subject>Cell Separation - statistics & numerical data</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>collection efficiency</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Mobilization</subject><subject>hematopoietic stem cells</subject><subject>Hematopoietic Stem Cells - cytology</subject><subject>Hematopoietic Stem Cells - immunology</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Middle Aged</subject><subject>optia</subject><subject>peripheral CD34 count</subject><subject>Quality Control</subject><subject>Retrospective Studies</subject><issn>0733-2459</issn><issn>1098-1101</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kdGK1DAUhoMo7jh64QtIwCvB7iZt07TeDXWdURZdRNG7kKQnbsa06SYddseH8son8MnM2N3FGyEQ-P__fAfOj9BTSo4pIfnJVsvjnBY1uYcWlDR1Rimh99GC8KLI8pI1R-hRjFtCSNMU7CE6yllFG97QBfq1OW-zFe58BDwG6KyerB9wetMFYD9OVv7-iTU4hyOMMsjJB6xkhO6QkVjBoC96Gb7j9jTH2jsHMwGMsdomd_8Knwff-8kO37B2drBaun_sl7hPWm9_HPzJXyd5SqIcOiyd81cH-XInXVITf5iCd4_RAyNdhCc3_xJ9fnP6qd1kZx_Wb9vVWabLipKsMxJUXlfaEGrKSnV1AarMueEVYaXmQEEx3kENzNSESd6VpsrTGWsOSqmqWKLnM3cM_nIHcRJbvwtDWikoZ5xRXqaDLtGLOaWDjzGAEWOw6SR7QYk49CNSP-JvPyn77Ia4Uz10d8nbQlLgZA5cWQf7_5PEu3Z1i8zmCRsnuL6bSJWIiheciS_v14K9bslm_ZWJj8UfQg-svg</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Cousins, Antony F.</creator><creator>Sinclair, Joy E.</creator><creator>Alcorn, Michael J</creator><creator>H.A. Green, Rachel</creator><creator>Douglas, Kenny W.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>201512</creationdate><title>HPC-A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control</title><author>Cousins, Antony F. ; Sinclair, Joy E. ; Alcorn, Michael J ; H.A. Green, Rachel ; Douglas, Kenny W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4610-dfaeb286cf01f46bd83eb427f76054c7e1eb57de8e5f805a7d4f6238087ebbb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antigens, CD34 - metabolism</topic><topic>Benchmarking</topic><topic>Blood Component Removal - instrumentation</topic><topic>Blood Component Removal - standards</topic><topic>Blood Component Removal - statistics & numerical data</topic><topic>Cell Count</topic><topic>Cell Separation - instrumentation</topic><topic>Cell Separation - standards</topic><topic>Cell Separation - statistics & numerical data</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>collection efficiency</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Mobilization</topic><topic>hematopoietic stem cells</topic><topic>Hematopoietic Stem Cells - cytology</topic><topic>Hematopoietic Stem Cells - immunology</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Middle Aged</topic><topic>optia</topic><topic>peripheral CD34 count</topic><topic>Quality Control</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cousins, Antony F.</creatorcontrib><creatorcontrib>Sinclair, Joy E.</creatorcontrib><creatorcontrib>Alcorn, Michael J</creatorcontrib><creatorcontrib>H.A. Green, Rachel</creatorcontrib><creatorcontrib>Douglas, Kenny W.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of clinical apheresis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cousins, Antony F.</au><au>Sinclair, Joy E.</au><au>Alcorn, Michael J</au><au>H.A. Green, Rachel</au><au>Douglas, Kenny W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HPC-A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control</atitle><jtitle>Journal of clinical apheresis</jtitle><addtitle>J. Clin. Apheresis</addtitle><date>2015-12</date><risdate>2015</risdate><volume>30</volume><issue>6</issue><spage>321</spage><epage>328</epage><pages>321-328</pages><issn>0733-2459</issn><eissn>1098-1101</eissn><abstract>It has been shown that it is possible to predict the CD 34+ hematopoietic progenitor cell dose from collection procedures on TerumoBCT COBE Spectra® cell separator platform using simple variables available at the start of the procedure. In this article, we demonstrate that this can be done simply and reliably using TerumoBCT Spectra Optia® (“Optia”) cell separator platform with a very close correlation between predicted and actual results (correlation coefficient 0.956). This knowledge can be used to optimize apheresis sessions and to minimize harmful effects and costs. In addition, we have shown differences in collection efficiency between healthy donors and cancer patients undergoing autologous donation. Finally, we have shown a small but significant improvement in collection efficiency for the Optia platform compared with the COBE Spectra platform. J. Clin. Apheresis 30:321–328, 2015. © 2015 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25619791</pmid><doi>10.1002/jca.21380</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0733-2459 |
| ispartof | Journal of clinical apheresis, 2015-12, Vol.30 (6), p.321-328 |
| issn | 0733-2459 1098-1101 |
| language | eng |
| recordid | cdi_proquest_journals_1757517499 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Antigens, CD34 - metabolism Benchmarking Blood Component Removal - instrumentation Blood Component Removal - standards Blood Component Removal - statistics & numerical data Cell Count Cell Separation - instrumentation Cell Separation - standards Cell Separation - statistics & numerical data Child Child, Preschool collection efficiency Female Hematopoietic Stem Cell Mobilization hematopoietic stem cells Hematopoietic Stem Cells - cytology Hematopoietic Stem Cells - immunology Humans Infant Male Middle Aged optia peripheral CD34 count Quality Control Retrospective Studies |
| title | HPC-A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T09%3A12%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HPC-A%20dose%20prediction%20on%20the%20optia%C2%AE%20cell%20separator%20based%20on%20a%20benchmark%20CE2%20collection%20efficiency:%20Promoting%20clinical%20efficiency,%20minimizing%20toxicity,%20and%20allowing%20quality%20control&rft.jtitle=Journal%20of%20clinical%20apheresis&rft.au=Cousins,%20Antony%20F.&rft.date=2015-12&rft.volume=30&rft.issue=6&rft.spage=321&rft.epage=328&rft.pages=321-328&rft.issn=0733-2459&rft.eissn=1098-1101&rft_id=info:doi/10.1002/jca.21380&rft_dat=%3Cproquest_cross%3E3923426471%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1757517499&rft_id=info:pmid/25619791&rfr_iscdi=true |